The $100 Billion Cancer Industry Doesn't Want You to See This

What's actually shaping your cancer care today? The titans, the big hospitals across the country or the trailblazers where precision oncology lives. For most people, it's chosen for them. The one size fits all model of the big hospital titans has built a massive scale population health program that goes through insurance, billing, big pharma and that's what most people are doing today. On today's episode, we're going to talk about the trailblazers versus the titans. Understanding the industry of cancer, how it impacts patient outcomes, where the innovations are and it may not be what you think. Hi, I'm Dr. Dr. Dino Prado, founder of Invita Medical Center. So the last 25 years my team and I have helped patients who failed some of the top cancer hospitals across the United States and we've helped them respond with precision oncology. So we're going to talk about what's the difference between the titans and the trailblazers. Well, the cancer drug spending has hit 252 billion in 2024, tracking towards 441 billion by 2029. We're going to ask who's really shaping both the prevention of cancer so we can avoid getting it in the first place and the treatment and the outcomes, especially for late stage dis. Go through these facilities and understand the difference because it's going to give you the information that most people don't know. And more importantly, how does this impact your choice in the prevention of cancer or treatment and the outcomes which is the most important thing based on sheer numbers. Most people are actually not in charge of their choice because the titans treat hundreds of thousands of patients a year. Most patients, even those who would prefer precision the trailblazer approach, targeted care with less side effects, don't really have that option because they don't know about it. Most people are referred into a titan model or standard of care model where the big industry, big insurance lives and our one size fits all planning is and today we'll break that down as we go through a little bit of the knowledge of both so you understand it and by understanding that it's going to give you the advantage. Now one of the keys to precision care is going to be that it's immune centric because in precision care you're utilizing DNA and next generation sequencing, RNA transcriptomics, immune spatial biology and you're treating each person as an n of 1, custom building it based on what they need. Then you're using on label drugs, off label, repurposed drugs, phytotherapeutics, plants, oxygen therapies, Integrative care to support the milieu. Get to the cause of the disease and you're building cancer cell vaccines. These are cellular biologics, natural killer cells, dendritic cells to target the cancer. This is a very advanced boutique, high level care that really a lot of people seek, but they don't know where to find it and how to use it. Unlike the titans who have already pretty much a standard playbook. And you're going to get the same care regardless of which hospital you go to in the country. After today's episode, you're going to be the 1% of the patients who understand this concept. There are really two major systems in the healthcare model and people don't know their options until they fail the stand others. But if you know your options up front, you can use them in prevention and in treatment. So today we'll compare the two worlds. Let's go through the titans number one titan, Mayo Clinic. You have MD Anderson, Dana Farber, Memorial Sloan Kettering. These are the industry giants representing the standard of care model. They impact and really define the massive scale of oncology. Extensive clinical trials, partnerships with big pharma, bringing in new drugs, new drug targets and into their facilities, huge dollars into the multi billions. And they put together world class teams of researchers all working in that mod where the trailblazers are immune centric precision oncology. It's What I've dedicated 25 years of my life doing, is building an ecosystem that customly builds care for the patient instead of the drug company as trailblazers, the goal is precision. Turning the patient's immune system on treating the root cause of the disease, developing the algorithms to properly target the best of conventional integrative care so you don't have the side effects but you get the benefits. And ultimately you allow your body's innate natural healing capacity to kick in. And so this is very different than the standard of care. These concepts are especially important to learn early, not after you've failed everything. My hope is that you'll find that precision care offers options you haven't seen before. But at the same time you can also see the benefits of standard of care modeling and also integrative care. Further, I'll try to provide clear steps to both and questions you can ask your doctors to get out of guesswork and into precision. So before we talk about details, it helps to understand the modern oncology system. After all, so much of the modern cancer treatment has to do with its roots. They come from warfare. Chemotherapy came from studying mustard gas during the war. And doctors found that it could suppress rapidly dividing white blood cells. So there was born the first chemotherapy, radiation therapy came out of simple physics that eventually were used to develop nuclear weapons. These are the roots of where standard oncology comes from. So we've inherited a medical paradigm that was shaped not from deep long term healing, but from short term survival. The titans have refined and standardized this model and in many ways they've saved millions of lives, especially in early stage disease with surgery removal. But they still are operating inside a system that was originally built as a kind on cancer by the Richard Nixon administration. Not precision repair the body and respect the body's intelligent design to heal. And still way too many patients die within the titan model, especially with late stage cancer. Let's take a look at Mayo Clinic. Three major sites, Arizona, Florida, Minnesota. They roughly treat 130,000 people with cancer every year. Huge experience with clinical trials and big pharma experience and trying to bring bring in partners to find and expand in the world of drugs. That's what they do. However, they're very weak in their integr program. Their integrative care in my opinion is really superficial. It focuses on helping people with nausea, fatigue, anxiety, that's fine. And their main treatments are acupuncture, mind, body and massage. I wouldn't call that integrative care, that's supportive care. But I think it's okay for them because it doesn't compete with their current model. It basically helps patients feel loved and supported so it has a place. But it's not really treating the root cause of their cancer. Their big game is partnering with big pharma to bring in individualized medicines that promise to lever functional digital omics, AI and bring in like new drugs by one actionable target at a time. If you're even lucky in these systems, you might even run a next generation sequencing DNA test. Let's say 30% of the patients even get access to this. And when they do, they're only going to find one drug for one target, which usually is to slow the cancer down, not kill it. I'm summarizing years of experience, but we have to also understand that when you run those targets, there are many drugs available off label, on label, phytotherapeutic, natural options, immune centric options, cancer cell vaccines. But you don't have access to it in those systems. So currently this is the approach that is running in the national compet comprehensive cancer guidelines. It's using the double blind placebo clinical trial population health. You treat everybody with the same type and stage of Cancer with the same treatment. If it works or a little better, or even just the same as another drug, it'll get to market. And most of the drugs we see are not really original drugs, they're plays off of old drugs. So it's basically how to get share of the market. But it doesn't really shift the game in survival and outcomes. That's unfortunately what we've seen over the years. And so this is where there is the money. This is the big pharma model. Treatments can vary from facility to facility depending on the equipment, radiation equipment that's owned, the type of clinical trials that they're allowing patients access to with late stage disease. But the scope is typically limited when it comes to access today to top level testing and AI and deep planning, it's maybe next generation sequencing with one drug that either is in a clinical trial or commercially available, which is very limiting. Not really a big change. Here we have next Dana Farber. Let's move right along. They treat about 96,000 patients. In the past year, their public offering has shown about 3 and a half billion in revenue in 24 through their institutions and affiliates. I mean these are massive institutions. They have huge pharma ties, they run industry partner discovery programs renewed with Novartis, other collaborations. They just have huge big pharma connections and a sizable share of the east coast market. If you go into Boston and on, it's owned by Dana Farber. And they open up all these satellites all over the place because their goal is to make it convenient for patients to fit in to their system into their billing models, which makes billions of dollars, years. I'm not saying it's bad, there's a place for it in early stage disease, but it's the standard of care. It works on the cancer industrial complex, insurance modeling, but it doesn't really have the deep learning that I'm talking about. In precision oncology. A lot of these doctors are trenched in the board certified oncology, which is fine. It's a standard of care training for oncology. I've done another episode on that you can watch. And I've trained board certified oncologists and all kinds of different backgrounds. DOS, MD, naturopaths. And when you come into precision oncology you need completely new training because it takes new training to understand all the molecular targets, the right algorithms and how to custom build the care. It's outside of standard of care. It's custom because each person has different markers. If you take two cancers with the same type and stage, there's Huge heterogeneity. They're different. And so in those markers we find the differences. We build the medicines and treat the patients very different than a one size fits all off the shelf care. Let's move on to MD Anderson, which is really huge. 190,000 patients and treated 1.7 million patient visits. It's unmatched in its scale and it won in the US for being the head of cancer care in 2025. But I'll share with you a little story. One of the doctors I know well took his wife there to get screening for breast cancer. And when he comp the tests that we run in precision oncology with MD Anderson, they said we don't do this here, we don't do any of that here. So they're big companies, they have huge pharmaceutical ties. They're trying to do things like microbiome and yoga and acupuncture for symptom control. Most of that in my opinion is very soft integrative care. It's not really changing the game in people living longer in outcomes. It provides some quality of life and it's kind of appeasing the public, but it's not getting to the root cause of the cancer. Again, this is the difference. And the reality is these massive systems can feel less personal. They have huge costs. I mean the average cost of cancer treatment has gone very high. It's not unusual to see late stage cancer patients who are spending over a million dollars of insurance care to get what they need. So this is one of the big ones. MD Anderson. Now let's go to Memorial Sloan Ketteran. And Sloan Ketteran is huge in New York City, 74,000 patients. In 2024, they logged about a million outpatient visits with 26,000 admissions. A huge engine in studies and trials. It's really a big part of their business model. With 8.1 billion in total operating revenue in 20. These guys are the titans. And yes, they have pharma ties. In 2024 alone, 11 FDA drug approvals were tied to Sloan Kettering played a key role in their studies. They also run programs that streamline industrial collaborations across drug development. So the reality is incredible depth for drug development and big pharma ties and scales. But it can feel super less personal because none of this is n of 1. It's usually following the NCCNN guidelines and if you fail, you're put into a drug trial. And it's a pharma centric model. You just have to money now. It's not good or bad. I'M just saying we need to do better as a country and we can. The titans, they partner closely with big pharma. These partnerships speed access to new drugs that can be sold globally. Imagine making a drug that works on one target and then you can mass produce it and sell it all over the world. This is a huge game. Now I'm not saying they don't have benefit, these drugs do and they can be helpful. But it's not the same of what I'm about to cover called N of one treatment planning which is custom built for each person. It's not one pathway, it's multiple. And so here's where the titans fall short. They're a massive model, very hard to shift, very hard to be flexible, very hard to move to newer technology because they're stuck in an old insurance billing model. And don't kid yourself, these are massive industries. So it runs off insurance. If they can't build it, you won't have access to it. And they are going to use the things they can build the most and profit the most at the same time. They're going to work with pharma on highly profitable new investments. They treat the masses, which is important, especially in early stage disease. The national Comprehensive Cancer Network guidelines has helped people. Step therapies can be helpful but it's not at the level of where we should be today. With the advanced advancements in AI and technology we should have the latest of care. Everybody deserves it. But you have to get out of the cancer industrial complex because it's built to handle the masses, it's standard of care. To me I think of it like socialized medicine. Everybody gets the same thing and it plays within this large insurance game and it limits people. Now this is so different than the trailblazers, the precision where everything is built on you and you're not just getting next generation sequencing but transcriptomics, immune spatial biology. Thousand plus data points with custom drug built that's designed for you. It doesn't work with pharmaceutical companies and A1 drug hit wonder. It works on finding what is right for you. And that's what we've been doing for the last 25 years. I think, and I say this without trying to give too much of an endorsement, but we're one of the best in the world at doing this. We've been doing this for 25 years and precision in my opinion is what's going to change the outcomes in cancer. We're already seeing it and we think it's going to get better. Think of the deep learning, think of all the algorithms that are available when you're looking at all of your targets, and then you can custom build the medicines and deliver them unique to each patient. Go direct to tumor use, minimally invasive use the latest technologies, change the nutrition, diet, microbiome, these all combining together to help our patients respond better. This is the difference with what I'd like to call the trailblazers. The smaller population by a lot, but it's what the public wants. We see this because we get calls from so many people each month that want to move to precision care or they failed the standard of care and they want more. But this is also different than what you might think you would find in integrative medicine. Integrative medicine is important. That's mainly what you'll see if you go online, watch YouTube, all the other social media you're going to find 99.9% is integrative medicine, which is great supportive care. Oxygen therapies, phytotherapeutic therapies, lifestyles, metabolic, and it has its place. But it's very different than precision, where precision actually does that, but it's all highly targeted. Years ago we got out of the guesswork, we used to be part of that. Then we started working with precision and the precision helped us really dial it in for patients by using both the best of conventional integrative with laboratory data that's called N of 1, where the treatment is custom built to the patient, not a clinical trial where you have to enroll and hope you have a marker to get a new drug. This is very different. And the reason is you're going to get a lot of new markers with precision oncology and with actionable treatments that are built to hit those markers versus in the conventional model, you're going to get some markers, but then only a few drugs that are approved for some of them and mainly nothing approved for most of them. That's where we are today. And until pharma develops a new drug for each one of those markers, you're just not going to see it. So we work with that. And then when we do that, we look at what the body can metabolize, what's causing the cancer, what's the root cause, how do we change the milieu, how do we improve the immunity? And so when you do that now, you can start reducing toxicity with micro dosing. And the key is to be immune centric. You've heard me talk about that so many times. Because the key to winning is long term immunity. So we oftentimes avoid surgery, radiation and high dose chemotherapy. And we get into targeting and precision. We know precision has a place and it'll get there. But it's not built into this full insurance billing model and it's not built into the cancer industrial complex. That's why people will not usually hear about it or get access to it until they need it or search for it on their own. And I've been doing this for 25 years. People just don't know the difference until they they need to know. I think we're in a unique time in history where people are getting more educated, they're trust the three letter organizations less and starting to do their own homework and that's helping a lot. And we're seeing a rise in integrative care, longevity care, biohacking, these are all great things. But we need to take it to another level in oncology because there's a complexity to care design when you're dealing with cancer and chronic diseases that go a little bit further than some of these simple recommendations. What N of 1 allows you to do is adapt quickly. So with lab testing we can see right away the treatments responding where before we see imaging stay on course or modified as we need to do. So it's very powerful. It's the reality that often you can have so much more control and care when you build it for the actual patient with clear targets and clear data for outcomes. So the titans, here's how we can compare them. They have unmatched manpower, unlimited financial dollars, partnerships with big pharma, big insurance. They are the leaders of the industry. I mentioned that Mayo Clinic, Dana Farber, Sloan Ketterin and MD Anderson, they're giants. They do great work in early stage disease in my opinion, later stage disease. I think there's much that can be done. The trailblazers smaller, much smaller communities but have tremendous technology that's moving head is more flexible as newer targeting, more planning, much more options that are helpful for patients. To me this is everything. This is the future of care. It removes the complexity of the biology and helps to bring in the individual care for each person. And it does this with custom combinations, direct to tumor approaches, avoiding side effects and helping people recover faster. That's what we've seen in our clinical experience where the titans are less personalized. They're trying to increase personalized medicine by developing one drug at a time with big Pharma and that's really in my opinion, not precision medicine. It's really not. It's what big pharma calls precision medicine. To me, precision medicine in the form of trailblazers or personalized care is where we look at all the markers and custom build all the combinations for each person. So we're totally talking about apples and oranges. And that makes a big difference because we have a much more comprehensive plan, a holistic ecosystem to help people uniquely map their cancer and provide better options using the best of integrated and conventional care with 25 years of clinical experience. So with titans it's more randomized, it's more large groups, clinical trials, trials. With the trailblazers in precision oncology it's real world experience signals moving quickly to help the patient and build the custom plan for each individual. That's the difference. So the titans, they have structure, money and programs but their integrative medicines, weak yoga, acupuncture, mind, body, that's not really integrative medicine. And any of you have been studying it in any form. You know that's pretty much nothing big there. Trailblazers which I'm talking about in precision oncology goes way beyond integrative medicine. It's not just nutrition and microbiome and some IV care. This is high level targeting that incorporates those things but where you need them and based on your target. So it gets the guesswork out whether using a repurposed drug on label drug or building a cancer cell vaccine just for you. That's the difference. It's immune centric and it really changes the game in cancer. So the real head to head is this titans standard of care protocols optimized for large populations. To me I like to call that really just one size fits all and pretty much it's standard of care. It's like socialized medicine. Everybody gets the same thing. It's the cancer industrial complex. It's what these large institutions can bill insurance and get high reimbursem assessments for. The trailblazers is very different. It's boutique, it's concierge, it's way ahead, maybe 10 or 15 years ahead of the curve with N of 1 targeting customization, minimally invasive procedures designed to match the unique tumor biology, build the custom immune system and help treat the cause of the disease with precision, not guesswork. That's the difference. So the precision oncology market is growing for about 126 billion in 2025 to 197 billion by 2030. But most of that is going to come by pharmaceutical companies trying to that was one drugs at a time for each target. Whether it's RNA or DNA markers. The titans very different than the trailblazers. We go much deeper in the biomarkers, thousands of markers. We shotgun them, test them all, and the algorithms tell us what the patient needs. And then we custom build the medicine for the patient. So we're already doing this at a much faster and higher level, but without the big pharma involvement. Because big pharma has no interest in repurposed drugs, oxygen therapies, has no interest in phytotherapeutic nutritional care. Anybody who knows medicine knows that you're not going to see anybody do studies on that because there's no money in that. You can't bill for it, but it's very powerful when you combine it with the right targets for each patient and about 20 new million cases of cancer expected. Meanwhile, global cancer incidences keep rising. So we need a better system to help people live a long and blessed life. Not to just be following into a system or fall into a clinical trial, but get a custom plan for them. We need to free the doctors and bring them into the right training and let the doctors make the full calls with the full laboratory data and the custom drug build. That's an entirely new ecosystem, one I don't think big pharma would like or big hospitals would like, because they make a lot of their money in this area. This is one of their top profitable areas, is cancer. And unfortunately, insurance companies are not interested in helping people. They're interested in their bottom line. So I don't think we're going to see these changes anytime soon. Because even though we're trying to make changes in the industry, it's going to come one patient at a time. Who makes the decision for themselves, does their homework, runs their tests, learns to ask their doctor the right questions so you can select the right care for you. That's the big difference. That's what you're going to see. And I can tell you we have toured many, many doctors through our campuses. Board certified oncologists, naturopathic doctors, top functional medicine doctors around the country. And they are blown away when they see the work we do. They've never seen this level of detail in targeting anywhere in the world. And I can say I'm excited about that because our goal is to make this available, get this out so patients can have it, and better yet, even have their insurance companies help cover the care. By the grace of God. It's not an easy process, but we're working to do that. The titans may be the best starting place for people because that's where they're referred, or to your local region where they may have an Office or get referred where the Trailblazers are. Precision N of 1 targeting gives you huge advantages to direct a tumor delivery. Find the right strategies, the combinations to help execute the best care. This is what you're going to see with precision oncology. So we avoid the guesswork and we get into better planning. We state evidence based on the individual's targets. So we're not treating populations or trying to develop a big drug for big pharma, but developing unique care for each person so they can respond. So what are the questions you can ask your doctor? Are you using any genetic testing, RNA transcriptomics, next gen generation, DNA immunospatial biology to custom build the plan for me? Instead of just pulling a drug off the shelf and giving it to me, Are you combining all this data to look at the root cause of my cancer? Is the treatment immune centric? Are you microdosing when you can to avoid toxicity to my organs and central nervous system and helping build my immune system? Are you combining the right treatments so that I have a better long term response by using an immune centric approach? These are basic questions you can ask and you'll get answers that usually will be like, well, we don't do this. This is not what we do. Or they may say, we'd love to do this, but we just don't have the infrastructure structure. Just like our good friend who went to MD Anderson and actually used to work there was a physician who used to work at MD Anderson and brought his wife there and asked if they could run the test that we run in precision oncology. And the answer was we just don't do that. So the titans may be the backbone of the cancer industrial complex today to treat the masses, but I don't think that's where the brilliant work is going to come. It's from the trailblazers because we're 10 to 15 years ahead with N of 1 targeting, meaning it's custom built on the patient. All the testing, all the targeting is on the patient. And then the treatment is built for them. It's custom built for each patient based on what they need. And this playbook isn't going to be sponsored by big pharma. It's going to be patients and doctors that want to win and help their patients live. It's about time that we take control of cancer technology so people can get the better care. So the titans, they're big, they're huge, they're global, they're powerful, but they have a lot of weaknesses. The trailblazers can help us get There faster. Get immune centric care. Get targeting. Bring your checklist in. Next time you see the doctor, ask for the mapping, look for the targeting, look for the immune centric care. This is going to help guide you and give you a huge advantage. It's a lot to talk about. We can go into this for a lot longer. But basically the chitons versus the trailblazers, the standard of care. NCCN guidelines one size fits all. Oncology versus precision N of one care that's customized for each patient. I believe the two definitely have a role in oncology. I've been doing it for two and a half decades and have seen how conventional care has failed so many patients and now how we've helped them respond or live longer with a better quality of life. And you just can't deny that. And most people don't know the difference because they don't work in the space. They need to get educated and learn their options so that they can take control of their health. I hope this was helpful. Helpful. And when it comes to prevention, I want you to think of it this way too. It's that same model trying to do prevention. So instead of like our mammograms and PSAs and these basic tests, we can run multi cancer tests. Screen it with one signal. If it's positive, image it. We haven't even done a biopsy yet. Find those cancers early, freeze them, remove them. Image guided. We don't need surgery. We can avoid radiation, avoid chemotherapy if we get to it early enough. And change the diet, the lifestyle, the microbiome, all those other videos I've made on nutrition you can watch to change our health. Get all the toxins out of our diet, all the chemicals, mycotoxins, infections. Clean those out of our bodies so that we can be healthy and reestablish our immune system. I hope this was helpful. And may the Lord bless you on your journey to healing.